Skip to main content
. 2021 Oct 7;61(2):321–333. doi: 10.1007/s40262-021-01068-0
The dosing regimen applied in the ALBINO trial leads to the targeted xanthine oxidase inhibition in hypoxic-ischemic encephalopathy (HIE) neonates treated with or without therapeutic hypothermia (TH).
The disease-related autoinhibition effect of allopurinol metabolism, as well as higher hypoxanthine, xanthine and uric acid initial levels, were identified in HIE neonates.
Clearances of allopurinol and oxypurinol were not significantly different between TH and non-TH patients.